USAMRMC SIGNS PATENT LICENSE AGREEMENT TO COMMERCIALIZE MOLECULAR TOOLS TO INCREASE THE ACCURACY OF HPV DIAGNOSIS AND INDICATE DISEASE SEVERITY
April 30, 2019
(Fort Detrick, Md.) -- The U.S. Army Medical Research and Materiel Command signed a patent license agreement with Gypsy Bay Genomics, Inc. to commercialize the Molecular Pap and HPV Discover, a novel biomarker-based diagnostic to indicate disease severity and detect emerging HPV genotypes for which no current diagnostic test exists. The technology, developed by Brook Army Hospital researcher Dr. Jane Shen-Gunther, is an in vitro diagnostic device based on comprehensive HPV genotyping and an epigenetic profile of novel biomarkers for precancerous cellular changes. The Molecular Pap has an advantage over traditional tests due to the ability to differentiate between grades of cervical cancer by molecular signature.
GBG recognizes the need to diagnose cervical cancer patients earlier, smarter, and less costly than is currently available. This patent license will allow GBG to develop the technology necessary to bring this diagnostic to market and will help guides clinicians in selecting the most appropriate therapy based on HPV carcinogenic potential.